Profound Medical (PROF) Net Cash Flow Growth (1y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -562.50% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -564.44% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 76.43% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -31.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -394.13% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 57.36% |
| 10 | Profound Medical | 244.28 Mn | 193.99 Mn | 3.83 Mn | -0.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.12% |
| Dec 31, 2025 | 17.95% |
| Sep 30, 2025 | -29.60% |
| Jun 30, 2025 | -101.47% |
| Mar 31, 2025 | -153.83% |
| Dec 31, 2024 | 492.61% |
| Sep 30, 2024 | -63.86% |
| Jun 30, 2024 | 59.31% |
| Mar 31, 2024 | 99.91% |
| Dec 31, 2023 | 80.18% |
| Sep 30, 2023 | -177.46% |
| Jun 30, 2023 | -178.73% |
| Mar 31, 2023 | 200.42% |
| Dec 31, 2022 | 4.78% |
| Sep 30, 2022 | -82.79% |
| Jun 30, 2022 | 508.03% |
| Mar 31, 2022 | -208.82% |
| Sep 30, 2021 | -18.91% |
| Jun 30, 2021 | -66.43% |
| Mar 31, 2021 | -75.18% |
| Sep 30, 2020 | 691.31% |
| Jun 30, 2020 | 36.00% |
| Mar 31, 2020 | 1,173.89% |
| Dec 31, 2019 | 159.65% |